Table 4.
Differences between BCT and mastectomy of new-onset breast cancer patients
| BCT n = 65,888 | Mastectomy n = 32,559 | p value | |
|---|---|---|---|
| Age in years, mean (SD) | 60.4 (11.3) | 60.7 (14.7) | 0.001 |
| Age groups | |||
| Under 40 years, N (%) | 2155 (48.1%) | 2321 (51.9%) | |
| 40–50 years, N (%) | 9510 (61.2%) | 6028 (38.8%) | |
| 50–75 years, N (%) | 48,393 (73.3%) | 17,620 (26.7%) | |
| Over 75 years, N (%) | 5830 (46.9%) | 6590 (53.1%) | |
| Socioeconomic status | < 0.001 | ||
| 0–9%, N (%) | 6067 (64.1%) | 3398 (35.9%) | |
| 10–20%, N (%) | 6290 (64.8%) | 3410 (35.2%) | |
| 20–30%, N (%) | 6270 (65.4%) | 3318 (34.6%) | |
| 30–40%, N (%) | 6448 (66.7%) | 3214 (33.3%) | |
| 40–50%, N (%) | 6689 (67.5%) | 3223 (32.5%) | |
| 50–60%, N (%) | 6466 (67.4%) | 3121 (32.6%) | |
| 60–70%, N (%) | 6558 (67.7%) | 3130 (32.3%) | |
| 70–80%, N (%) | 6840 (68.0%) | 3216 (32.0%) | |
| 80–90%, N (%) | 7075 (69.4%) | 3124 (30.6%) | |
| 90–100%, N (%) | 7185 (67.8%) | 3405 (32.2%) | |
| Tumor stage | < 0.001 | ||
| Stage I, N (%) | 45,920 (78.3%) | 12,697 (21.7%) | |
| Stage II, N (%) | 19,968 (50.1%) | 19,862 (49.9%) | |
| Medical history | < 0.001 | ||
| No medical history, N (%) | 61,375 (67.3%) | 29,766 (32.7%) | |
| Positive non-oncological medical history, N (%) | 4372 (63.2%) | 2546 (36.8%) | |
| Positive oncological medical history, N (%) | 141 (36.3%) | 247 (63.7%) | |
| Hormone receptor status | |||
| Her2receptor negative, N (%) | 59,057 (67.8%) | 28,008 (32.2%) | < 0.001 |
| Progesterone receptor positive, N (%) | 45,924 (68.4%) | 21,265 (31.6%) | < 0.001 |
| Estrogen receptor positive, N (%) | 55,295 (68.0%) | 26,028 (32.0%) | < 0.001 |
| Triple negative, N (%) | 2076 (55.3%) | 1681 (44.7%) | < 0.001 |
| Tumor grade | < 0.001 | ||
| Low grade, N (%) | 18,762 (75.7%) | 6014 (24.3%) | |
| Intermediate grade, N (%) | 31,109 (65.5%) | 16,415 (34.5%) | |
| High grade, N (%) | 16,017 (61.3%) | 10,130 (38.7%) | |
| Histological tumor type | < 0.001 | ||
| No special type, N (%) | 55,100 (69.3%) | 24,360 (30.7%) | |
| ILC, N (%) | 6192 (53.7%) | 5344 (46.3%) | |
| Both, N (%) | 1560 (51.3%) | 1481 (48.7%) | |
| Mucinous, N (%) | 1200 (68.3%) | 556 (31.7%) | |
| Medullary, N (%) | 399 (67.2%) | 195 (32.8%) | |
| Tubular, N (%) | 750 (83.5%) | 148 (16.5%) | |
| Other, N (%) | 687 (59.1%) | 475 (40.9%) | |
| Neo-adjuvant therapy, N (%) | 7940 (61.9%) | 4893 (38.1%) | < 0.001 |
| Adjuvant therapy, N (%) | 64,576 (77%) | 19,337 (23%) | < 0.001 |
| Detected during screening | 31,574 (47.9%) | 7796 (23.9%) | < 0.001 |
| Hospital volume | < 0.001 | ||
| Low volume | 5825 (63.6%) | 3341 (36.4%) | |
| Average volume | 15,876 (65.3%) | 8426 (34.7%) | |
| High volume | 44,187 (68%) | 20,792 (32%) | |
| Year of diagnosis | < 0.001 | ||
| 2011, N (%) | 7411 (62.2%) | 4497 (37.8%) | |
| 2012, N (%) | 7754 (63.7%) | 4426 (36.3%) | |
| 2013, N (%) | 7943 (64.6%) | 4347 (35.4%) | |
| 2014, N (%) | 8103 (65.7%) | 4229 (34.3%) | |
| 2015, N (%) | 8178 (66.3%) | 4151 (33.7%) | |
| 2016, N (%) | 8602 (69.8%) | 3722 (30.2%) | |
| 2017, N (%) | 9009 (70.9%) | 3691 (29.1%) | |
| 2018, N (%) | 8888 (71.8%) | 3496 (28.2%) | |
BCT breast conserving therapy, N number, SD standard deviation, ILC invasive lobular carcinoma